Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer

Neoplasia (United States)

Volumn 16, Issue 2, 2014, Pages 137-146

  Nör, Carolina ^a,b,c   Zhang, Zhaocheng ^a   Warner, Kristy A ^a   Bernardi, Lisiane ^a   Visioli, Fernanda ^b   Helman, Joseph I ^a   Roesler, Rafael ^b,c   Nör, Jacques E ^a,d,e  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c National Institute for Translational Medicine INCT TM   (Brazil)

^d University of Michigan   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; BMI1 PROTEIN; CISPLATIN; HERMES ANTIGEN; INTERLEUKIN 6; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; BMI1 PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENOTYPE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CANCER STEM CELL; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HEAD AND NECK NEOPLASMS; METABOLISM; PATHOLOGY; SCID MOUSE; TRANSCRIPTION INITIATION; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; MICE, SCID; NEOPLASTIC STEM CELLS; POLYCOMB REPRESSIVE COMPLEX 1; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900456376     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131744     Document Type: Article

References (48)

1. Chen Z (2009). The cancer stem cell concept in progression of head and neck cancer. J Oncol 2009, 894064.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D (2011). Global cancer statistics. CA Cancer J Clin 61, 69-90.
3. Department of Veterans Affairs Laryngeal Cancer Study Group (1991). Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324, 1685-1690.
4. Genden EM, Ferlito A, Bradley PJ, Rinaldo A, and Scully C (2003). Neck disease and distant metastases. Oral Oncol 39, 207-212.
5. Forastiere AA (2008). Chemotherapy in the treatment of locally advanced head and neck cancer. J Surg Oncol 97, 701-707.
6. Sano D and Myers JN (2007). Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev 26, 645-662.
7. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CHM, Jones DL, Visvader J, Weissman IL, and Wah GM (2006). Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 66, 9339-9344.
8. Gupta PB, Chaffer CL, and Weinberg RA (2009). Cancer stem cells: mirage or reality? Nat Med 15, 1010-1012.
9. Reya T, Sean J, Morrison SJ, Clarke MF, and Weissman IL (2001). Stem cells, cancer, and cancer stem cells. Nature 414, 105-111.
10. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, and Clarke MF (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100, 3983-3988.
11. Korkaya H, Kim G, Davis A, Malik F, Henry NL, Ithimakin S, Ahmed A, Quraishi AA, Tawakkol N, D'Angelo R, et al. (2012). Activation of an IL-6 inflammatory loop mediates trastuzumab resistance in her2+ breast cancer by expanding the cancer stem cell population. Mol Cell 47, 570-584.
12. Liu YP, Yang CJ, Huang MS, Yeh CT, Wu AT, Lee YC, Lai TC, Lee CH, Hsiao YW, Lu J, et al. (2012). Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res 73, 406-416.
13. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, and Parada LF (2012). A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522-526.
14. Visvader JE and Lindeman GJ (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8, 755-768.
15. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, and Ailles LE (2007). Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104, 973-978.
16. Krishnamurthy S, Dong Z, Vodopyanov D, Imai A, Helman JI, Prince ME, Wicha MS, and Nör JE (2010). Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res 70, 9969-9978.
17. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, et al. (2001). The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7, 1028-1034.
18. Goodell MA, Rosenzweig M, Kim H, Marks DF, DeMaria M, Paradis G, Grupp SA, Sieff CA, Mulligan RC, and Johnson RP (1997). Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 3, 1337-1345.
19. Scharenberg CW, Harkey MA, and Torok-Storb B (2002). The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99, 507-512.
20. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, et al. (2007). A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69-82.
21. Polyak K and Weinberg RA (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9, 265-273.
22. Neiva KG, Zhang Z, Miyazawa M, Warner KA, Karl E, and Nör JE (2009). Crosstalk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia 11, 583-593.
23. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, et al. (2007). IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117, 3988-4002.
24. Marotta LLC, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, et al. (2011). The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors. J Clin Invest 121, 2723-2735.
25. Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, Wolf GT, and Teknos TN (2008). Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 15, 750-757.
26. Nör JE, Peters MC, Christensen JB, Sutorik MM, Linn S, Khan MK, Addison CL, Mooney DJ, and Polverini PJ (2001). Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest 81, 453-463.
27. Zeitlin BD, Joo E, Dong Z, Warner K, Wang G, Nikolovska-Coleska Z, Wang S, and Nör JE (2006). Antiangiogenic effect of TW37, a small-molecule inhibitor of bcl-2. Cancer Res 66, 8698-8706.
28. Krishnamurthy S and Nör JE (2013). Orosphere assay: a method for propagation of head and neck cancer stem cells. Head Neck 35, 1015-1021.
29. Negoro K, Yamano Y, Fushimi K, Saito K, Nakatani K, Shiiba M, Yokoe H, Bukawa H, Uzawa K, Wada T, et al. (2007). Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB. Int J Oncol 30, 1325-1332.
30. Van Tubergen E, Vander Broek R, Lee J, Wolf G, Carey T, Bradford C, Prince M, Kirkwood KL, and D'Silva NJ (2011). Tristetrapolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma. Cancer 117, 2677-2689.
31. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ, and Clarke MF (2003). Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302-305.
32. Wu Z, Min L, Chen D, Hao D, Duan Y, Qiu G, and Wang Y (2011). Overexpression of Bmi-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma. PloS One 6, e14648.
33. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, et al. (2007). Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117, 3846-3856.
34. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, and Kim JD (2000). Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA 97, 4227-4232.
35. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, et al. (2011). Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 15, 614-624.
36. Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, Eyler CE, Elderbroom J, Gallagher J, Schuschu J, et al. (2009). Targeting interleukin-6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 27, 2393-2404.
37. Tsao HK, Chiu PH, and Sun SH (2013). PKC-dependent ERK phosphorylation is essential for P2X7 receptor-mediated neuronal differentiation of neural progenitor cells. Cell Death Dis 4, e751.
38. Massagué J (2004). G1 cell-cycle control and cancer. Nature 432, 298-306.
39. Boulikas T and Vougiouka M (2004). Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep 11, 559-595.
40. Marur S and Forastiere AA (2010). Update on role of chemotherapy in head and neck squamous cell cancer. Indian J Surg Oncol 1, 85-95.
41. Ailles LE and Weissman IL (2007). Cancer stem cells in solid tumors. Curr Opin Biotechnol 18, 460-466.
42. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, et al. (2009). Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780-783.
43. Diehn M, Cho RW, and Clarke MF (2009). Therapeutic implications of the cancer stem cell hypothesis. Semin Radiat Oncol 19, 78-86.
44. Hodge DR, Hurt EM, and Farrar WL (2005). The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41, 2502-2512.
45. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, and Rincón M (2001). Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61, 8851-8858.
46. Ara T, Song L, Shimada H, Keshelava N, Russell HV, Metelitsa LS, Groshen SG, Seeger RC, and DeClerck AY (2009). Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 69, 329-337.
47. Poth KJ, Guminski AD, Thomas GP, Leo PJ, Jabbar IA, and Saunders NA (2010). Cisplatin treatment induces a transient increase in tumorigenic potential associated with high interleukin-6 expression in head and neck squamous cell carcinoma. Mol Cancer Ther 9, 2430-2439.
48. Sugimura K, Miyata H, Tanaka K, Hamano R, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, et al. (2012). Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res 18, 5144-5153.